Reuters Market Eye - Morgan Stanley upgrades Biocon Ltd to "overweight" from "equal-weight" and raises its target price to 392 rupees from 283 rupees, citing improving base business, progress in the bio-similar platform and inexpensive valuations.
"Biocon has made good progress in Phase III clinical trials for human insulin for EU markets. The company targets a dossier filing in the next few months," Morgan Stanley said in a report.
Also on watch, company to report its June-quarter results on Thursday.
Shares in Biocon are up 2.7 percent to 314 rupees at 11 a.m.
(Reporting by Abhishek Vishnoi)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app